Combined General Meeting of

General Meeting of May 19, 2022

of the preparatory documents

(France), Long Island City (New York, United States), April 28, 2022 - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage

biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis

(NASH) and other diseases with significant unmet medical needs, today announced the availability of the preparatory documents for the

Combined General Meeting of May 19, 2022.

are invited to participate in the annual Combined General Meeting that will be held on May 19, 2022 at 2 p.m. at H tel

Oceania Le Jura, 14 avenue Foch, 21000 Dijon (France).

preliminary notice of meeting comprising the agenda and the draft resolutions, as well as information on how to attend and vote at the

Combined General Meeting, was published in the Bulletin des Annonces L gales Obligatoires (BALO) n 43 of April 11, 2022

and a translation was filed with the Securities and Exchange Commission on April 11, 2022.

and documents pertaining to the Combined General Meeting are available in the Company's website (www.inventivapharma.com, section "Investors"

/ "Shareholder Meetings").

accordance with articles R. 225-83 and R. 225-89 of the French Commercial Code, documents that must be available for the shareholders

for the purpose of general meetings will be available at the Company's registered office, 50, Rue de Dijon, 21121 Daix, the fifteenth

day prior to the Combined General Meeting.

listed in Article R.22-10-23 of the French Commercial Code are available on Inventiva's website mentioned above as from today,

the twenty-first day that precedes the General Meeting.

accordance with applicable regulatory provisions:

is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment

of NASH and other diseases with significant unmet medical need. The Company benefits from a strong expertise and experience in the domain

of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva's lead product candidate,

lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with NASH, a common and

progressive chronic liver disease for which there are currently no approved therapies.

Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases that resulted in the discovery of the

drug candidate cedirogant (ABBV-157), an oral ROR inverse agonist which is being evaluated in a Phase IIb clinical trial, led

by AbbVie, in adult patients with moderate to severe chronic plaque psoriasis. Inventiva's pipeline also includes odiparcil, a

drug candidate for the treatment of adult mucopolysaccharidoses (MPS) VI patients. As part of Inventiva's decision to focus clinical

efforts on the development of lanifibranor, it suspended clinical efforts relating to odiparcil and is reviewing available options with

respect to its potential further development. Inventiva is in the process of selecting an oncology development candidate for its Hippo

signalling pathway program.

Company has a scientific team of approximately 80 people with deep expertise in the fields of biology, medicinal and computational chemistry,

pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically

relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility.

is a public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA - ISIN: FR0013233012) and on the Nasdaq

Global Market in the United States (ticker: IVA). www.inventivapharma.com.

press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities

Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking

statements. These statements include, but are not limited to, forecasts and estimates with respect to Inventiva's pre-clinical

programs and clinical trials, pipeline and preclinical and clinical development plans, future activities, expectations, plans, growth

and prospects of Inventiva. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without

limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks",

"estimates", "may", "will", "would", "could", "might", "should",

and "continue" and similar expressions. Such statements are not historical facts but rather are statements of future expectations

and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing

as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or

future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may

depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that

the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated,

that product candidates will receive the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva or its

partners will be reached on their expected timeline, or at all. Actual results may turn out to be materially different from the anticipated

future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors,

including that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has

incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from

product sales, Inventiva will require additional capital to finance its operations, Inventiva's future success is dependent

on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates,

preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's clinical

trials may not support Inventiva's product candidate claims, Inventiva may encounter substantial delays in its clinical trials or

Inventiva may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, enrollment and retention

of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by

multiple factors outside Inventiva's control, Inventiva's product candidates may cause adverse drug reactions or have other properties

that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition

and Inventiva's business, and preclinical studies and clinical development programs and timelines, its financial condition and

results of operations could be materially and adversely affected by the current COVID-19 pandemic and geopolitical events, such as the

conflict between Russia and Ukraine, which could delay the initiation, enrolment and completion of Inventiva's clinical trials

on anticipated timelines or at all. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of

such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak

as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

refer to the Universal Registration Document for the year ended December 31, 2021 filed with the Autorit des March s

Financiers on March 11, 2022 and the Annual Report on Form 20-F for the year ended December 31, 2021 filed with the Securities

and Exchange Commission on March 11, 2022 for additional information in relation to such factors, risks and uncertainties.

information in this press release is as of the date of the release. Except as required by law, Inventiva has no intention and is

under no obligation to update or review the forward-looking statements referred to above.